ライフサイエンスコーパス: pioglitazone

1 tion of PPARgamma agonists (rosiglitazone or pioglitazone).

2 s (T2DM) seem to be specifically targeted by pioglitazone.

3 d and T cell proliferation was unaffected by pioglitazone.

4 drome, with the thiazolidinedione class drug pioglitazone.

5 class of anti-diabetic medications including pioglitazone.

6 ned CMR, up to 4.7 years after withdrawal of pioglitazone.

7 of inflammatory cytokines were resistant to pioglitazone.

8 omologs, E75 and E78, are in vivo targets of pioglitazone.

9 to those from an equivalent dose of racemic pioglitazone.

10 treatment with the insulin-sensitizing agent pioglitazone.

11 r changes were observed in mice treated with pioglitazone.

12 a novel target of the type II diabetes drug pioglitazone.

13 nsulin sensitivity was seen after 21 days of pioglitazone.

14 in obese mice by the thiazolidinedione drug pioglitazone.

15 hese effects were at par with or superior to pioglitazone.

16 s reversed by diet or the insulin sensitizer pioglitazone.

17 class of anti-diabetic medications including pioglitazone.

18 ominal adipocytes from subjects treated with pioglitazone.

19 ed PASMC proliferation that was prevented by pioglitazone.

20 tor dapagliflozin and the insulin sensitizer pioglitazone.

21 iated inflammation in mice were resistant to pioglitazone.

22 lcohol seeking was prevented by infusions of pioglitazone (0, 2.5, 5, and 10 mug/mul) in the CeA, VTA

23 Bilateral infusions of pioglitazone (0, 5, and 10 mug/mul) in the rostromedial

24 63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin ve

25 74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin ve

26 rms (vildagliptin: -0.1%+/-0.3%; P=0.046 and pioglitazone: -0.2%+/-0.3%; P=0.029).

27 n, 15.4 [5.5] vs 4.5 [2.4] mug/mL, P < .001; pioglitazone, 12.6 [3.6] vs 4.8 [0.6] mug/mL, P < .001).

28 roups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).

29 rmin, 1.8 at study entry to 0.1 at month 24; pioglitazone, 2.2 at study entry to 0.3 at month 24).

30 rmin, 2.5 at study entry to 0.5 at month 24; pioglitazone, 2.3 at study entry to 0.6 at month 24), as

31 e (vildagliptin: -20+/-24 mg/dL; P=0.002 and pioglitazone: -23+/-29 mg/dL; P=0.004), and pioglitazone

32 a-2a plus ribavirin for 48 weeks, n = 73) or pioglitazone 30-45 mg/day plus standard care (n = 77) in

33 Pioglitazone (30 mg/kg weight) was administered orally 1

34 ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg/kg).

35 in, 5.5 [2.4] vs 10.5 [3.4] ng/mL, P < .001; pioglitazone, 4.1 [0.8] vs 11.0 [2.6] ng/mL, P < .001) a

36 rticipants were randomly assigned to receive pioglitazone (45 mg/d target dose) or placebo within 180

37 aloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followe

38 Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatmen

39 metformin, 6.7 [1.5] vs 2.1 [1.0], P = .001; pioglitazone, 6.9 [0.8] vs 3.0 [0.8], P = .001).

40 by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25

41 We hypothesized that pioglitazone, a peroxisome proliferator-activated recept

42 dition of lipids, and studied the effects of pioglitazone, a peroxisome proliferator-activated recept

43 was restored in cells that were treated with pioglitazone, a PPARgamma agonist, before infection with

44 Importantly, our data show that pioglitazone, a PPARgamma agonist, significantly inhibit

45 Here we have shown that pioglitazone, a selective peroxisome proliferative-activ

46 sults showed that activation of PPARgamma by pioglitazone abolished the expression of somatic and aff

47 Pioglitazone-activated PPARgamma binds to Smad3 in human

48 In conclusion, pioglitazone acutely induces whole-body metabolic slowin

49 to determine if the insulin-sensitizing drug pioglitazone acutely reduces insulin secretion and cause

50 as reduced in both Wistar and ZDF rats after pioglitazone administration.

51 e proliferator-activated receptor-gamma with pioglitazone alone is not sufficient to promote differen

52 Pioglitazone also reduced energy expenditure in Wistar r

53 Pioglitazone also reduced the risk of type 1 MI (hazard

54 pioglitazone: -23+/-29 mg/dL; P=0.004), and pioglitazone also significantly improved fasting plasma

55 se treatment of diabetic obese patients with pioglitazone, an antidiabetic and antiinflammatory PPARg

56 The PPARgamma agonist pioglitazone and a novel selective PPARalpha/gamma modul

57 gamma binding assays (affinity comparable to pioglitazone and arachidonic acid), and in vitro murine

58 uced TFH cell responses in female mice while pioglitazone and estradiol (E2) co-treatment ameliorated

59 tablished treatments for insulin resistance (pioglitazone and exenatide) as possible disease modifyin

60 om 2004-2010, we analyzed the association of pioglitazone and incidence of dementia in a prospective

61 a is activated by thiazolidinediones such as pioglitazone and is targeted to treat insulin resistance

62 The use of pioglitazone and rosiglitazone is associated with a decr

63 Pioglitazone and rosiglitazone possess a common function

64 tration of synthetic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates PPAR-gamma-

65 s of two variants of the glitazone scaffold, pioglitazone and rosiglitazone, in an effort to identify

66 f specific cancer types may be different for pioglitazone and rosiglitazone.

67 -3.5 +/- 1.71 and -3.7 +/- 1.62 IU/mL in the pioglitazone and standard-care groups, respectively, Del

68 atohepatitis [NASH]) trial demonstrated that pioglitazone and vitamin E improved liver histology to v

69 Pharmacologic therapies (such as pioglitazone and vitamin E) should be considered only in

70 ith prescriptions of <8 calendar quarters of pioglitazone, and diabetics with >/=8 quarters.

71 ments with proven benefit include vitamin E, pioglitazone, and obeticholic acid; however, the effect

72 mice were treated with the PPARgamma agonist pioglitazone, and phagocyte ROS and killing of S aureus

73 FP to inhibit the pro-adipogenic response to pioglitazone, and that the ability of pioglitazone to de

74 PPAR-gamma agonists, like pioglitazone, appear antiproteinuric.

75 Pioglitazone appeared to have its most prominent effect

76 The effect of pioglitazone appears to be a direct action on beta cells

77 ed receptor (PPAR) gamma agonists, including pioglitazone, approved for type 2 diabetes therapy alter

78 PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use for the treatment of in

79 data demonstrate that both vildagliptin and pioglitazone are of potential benefit in patients with I

80 ackground Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications u

81 dinediones (TZDs), such as rosiglitazone and pioglitazone, are peroxisome proliferator-activated rece

82 , and support the feasibility of translating pioglitazone as a novel pharmacotherapy of PAP.

83 Meta-analysis supported pioglitazone as an effective treatment option for T2DM p

84 mpounds, we identified the PPARgamma agonist pioglitazone as neuroprotective in Drosophila.

85 umulative dose, and time since initiation of pioglitazone as time dependent.

86 )=0.960, P<0.0001) 12weeks of treatment with pioglitazone as well as from control subjects (R(2)=0.89

87 c-euglycemic clamp was minimally affected by pioglitazone at this early time point.

88 Treatment with pioglitazone before and during treatment with peginterfe

89 ells in the presence of the PPARgamma ligand pioglitazone, but this trans-differentiation is inhibite

90 Here, we show that pioglitazone can rescue TDP-43-dependent locomotor dysfu

91 roach, we identify a set of metabolites that pioglitazone can restore in the context of TDP-43 expres

92 beta1 signals and that the PPARgamma agonist pioglitazone can restore vascular homeostasis and preven

93 or MI derive a greater absolute benefit from pioglitazone compared with patients at lower risk.

94 Islets from animals treated with pioglitazone concurrently with HFD demonstrated a revers

95 e findings together suggest that repurposing pioglitazone could potentially enhance the proteinuria-r

96 F11 genetic deficiency effectively abolished pioglitazone cytoprotection in mouse cerebral vascular e

97 Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or n

98 shed between nondiabetics, diabetics without pioglitazone, diabetics with prescriptions of <8 calenda

99 esults show that stimulation of PPARgamma by pioglitazone did not affect basal anxiety, but fully pre

100 ients with a recent ischaemic stroke or TIA, pioglitazone did not affect cognitive function, as measu

101 Troglitazone and pioglitazone differ in their influence on SSC.

102 ic monophosphate sodium salt (8-Br-cGMP), or pioglitazone dose-dependently downregulated podocyte inj

103 ypothesis, female NOD mice were administered pioglitazone during the pre-diabetic phase and assessed

104 and shRNA knockdown of PPFP eliminated this pioglitazone effect.

105 ion; however, when combined, cholesterol and pioglitazone enhance OPC differentiation into mature OLs

106 lysis revealed that both glucocorticoids and pioglitazone enhanced glomerular synaptopodin and nephri

107 rt-term treatment of gp91(phox-/-) mice with pioglitazone enhanced stimulated ROS production in neutr

108 act as a stereoselective barrier to prevent pioglitazone entry into the brain.

109 Pioglitazone exerted its positive effect by inhibition o

110 Pioglitazone exhibited improved glucose uptake within 3

111 y devoid of HSPC-retaining activity, whereas pioglitazone failed to downregulate Cxcl12 in BM adipocy

112 hemoattractant factors after only 10 days of pioglitazone, followed by a 69% reduction in ATM content

113 ion, and patients who undergo treatment with pioglitazone for longer durations (>12 months) or are ad

114 Within each stratum, the efficacy of pioglitazone for preventing stroke or MI was calculated.

115 a double-blind, placebo-controlled trial of pioglitazone for secondary prevention.

116 nd showed that feeding the PPARgamma agonist pioglitazone greatly decreased the size of the primary t

117 5-year risk for stroke or MI was 6.0% in the pioglitazone group among patients at lower baseline risk

118 ared mean 3MS score increased by 0.27 in the pioglitazone group and by 0.29 in the placebo group (mea

119 curred in 175 of 1939 patients (9.0%) in the pioglitazone group and in 228 of 1937 (11.8%) in the pla

120 After 16 weeks, compared to placebo, the pioglitazone group had a significant reduction in Adipo-

121 ts at higher risk, the risk was 14.7% in the pioglitazone group vs 19.6% for placebo (absolute risk d

122 %) in the placebo group (hazard ratio in the pioglitazone group, 0.76; 95% confidence interval [CI],

123 Treatment with metformin and pioglitazone has beneficial anti-inflammatory effects in

124 The results suggest that pioglitazone has direct metabolic deceleration effects o

125 stion with a high-fat diet (HFD) or HFD plus pioglitazone (HFD-P), we demonstrate that the fractions

126 arably to high-dose glucocorticoids, whereas pioglitazone + high-dose glucocorticoids reduced protein

127 g of the salt disproportionation reaction of pioglitazone hydrochloride (PIO-HCl) at a very low drug

128 re benefit from the insulin-sensitizing drug pioglitazone hydrochloride compared with patients at low

129 , 850 to 1500 mg/d, and 10 patients received pioglitazone hydrochloride, 15 to 30 mg/d; 20 untreated

130 or MetS, such as metformin hydrochloride and pioglitazone hydrochloride, have been demonstrated, alth

131 amyloid-lowering capabilities to the racemic pioglitazone in an in vitro AD model.

132 oglitazone was 46.6% higher than that of (-)-pioglitazone in brain tissue and 67.7% lower than that o

133 GIIS) and oxygen consumption were reduced by pioglitazone in isolated islets and INS832/13 cells.

134 re, the binding of the type II diabetes drug pioglitazone in mitoNEET effectively inhibits the thiol-

135 rain tissue and 67.7% lower than that of (-)-pioglitazone in plasma.

136 Microinjections of pioglitazone in the ventral tegmental area (VTA), centra

137 nt with PPARgamma agonists (rosiglitazone or pioglitazone) in primary cultures of mouse glial cells r

138 ent of NASH include the use of vitamin E and pioglitazone, in addition to dietary counseling and regu

139 ormed a secondary analysis of the effects of pioglitazone, in comparison with placebo, on acute coron

140 he remaining PPARgamma in Pparg(C/-) mice by pioglitazone increased S1P1 levels, reduced the Th17 pop

141 In terms of population regions, pioglitazone increased the risk for bladder cancer could

142 Pioglitazone increased weight less among patients at hig

143 al years as to whether the antidiabetic drug pioglitazone increases the risk for bladder cancer.

144 Our data show that pioglitazone induced cellular lipid accumulation and the

145 ystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is as

146 Pioglitazone inhibited the canonical TGFbeta1-CTGF axis

147 ed to protracted abstinence is attenuated by pioglitazone injected into the amygdala.

148 Dosing with (+)-pioglitazone instead of the racemic mixture may result i

149 Microinjection of pioglitazone into the AMY, but not into the HIPP, abolis

150 his finding, site-specific microinjection of pioglitazone into the RMTg but not into the VTA reduced

151 sting additional models of ALS, we find that pioglitazone is also neuroprotective when FUS, but not S

152 Pioglitazone is beneficial in improving liver histology

153 Pioglitazone is contraindicated in patients with HF>New

154 Pioglitazone is currently undergoing clinical trials for

155 Pioglitazone is suggested to prescribe following individ

156 nhibitor (imatinib) and a thiazolidinedione (pioglitazone) is proposed for the treatment of chronic m

157 oNEET, a target of the type II diabetes drug pioglitazone, is a key regulator of energy metabolism in

158 Dosing mice with pure (+)-pioglitazone led to a 76% increase in brain exposure lev

159 nformatic drug repurposing analyses (such as pioglitazone, levonorgestrel, salsolidine, ginkgolide A,

160 Remarkably, pioglitazone + low-dose glucocorticoids also reduced pro

161 If diabetes patients used pioglitazone <8 quarters, the dementia risk was comparab

162 uction of [2Fe-2S] clusters, suggesting that pioglitazone may modulate the function of mitoNEET by bl

163 enhanced glycolysis in the cytosol and that pioglitazone may regulate energy metabolism in mitochond

164 bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2.8 years; range, 0.2-13.

165 after oxygen-glucose deprivation, as well as pioglitazone-mediated cerebrovascular protection in a mo

166 tic cancer risks associated with ever use of pioglitazone merit further investigation to assess wheth

167 with protracted abstinence was prevented by pioglitazone microinjection into the amygdala.

168 ntrast, treatment with the PPARgamma agonist pioglitazone mimicked selenium supplementation.

169 Pioglitazone monotherapy showed equivalent efficacy as c

170 ystematic review and meta-analysis comparing pioglitazone monotherapy with monotherapies of other ora

171 % CI: -1.70 to 0.28) were also observed with pioglitazone monotherapy.

172 and the long-term effects (>/=3.6 years) of pioglitazone needs be monitored more carefully.

173 Osm deletion recapitulated the effects of pioglitazone on adipogenesis, which was p66Shc independe

174 It can be assumed that the effects of pioglitazone on beta-cells are negligible under in vivo

175 We tested the influence of troglitazone and pioglitazone on different parameters of SSC, including i

176 The effect of pioglitazone on liver metastasis was assessed.

177 nglion neurons revealed a salutary effect of pioglitazone on pathways related to defense and cytokine

178 for ischemic stroke to examine the effect of pioglitazone on stroke outcomes.

179 events in this population and the impact of pioglitazone on these events have not been described.

180 the temporal relationship of the effects of pioglitazone on these two parameters.

181 ic conditions, to investigate the effects of pioglitazone on TNFalpha, SOCS3, and downstream insulin

182 estigate the effect of the PPARgamma agonist pioglitazone on tumor metastasis and liver injury follow

183 nediones (TZDs), including rosiglitazone and pioglitazone, on cardiac tissue.

184 ) WDSW alone, (2) WDSW + vehicle, (3) WDSW + pioglitazone or (4) WDSW + saroglitazar for an additiona

185 Pioglitazone or its analog NL-1 appears to inhibit the e

186 Pioglitazone or matching placebo.

187 fits of lifestyle modification alone or with pioglitazone or vitamin E in a cohort of patients aged 5

188 le modification alone, treatment with either pioglitazone or vitamin E in addition to lifestyle modif

189 siglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively

190 nhibitor vildagliptin, the thiazolidinedione pioglitazone, or placebo for 3 months in addition to lif

191 sulin glargine, insulin lispro, liraglutide, pioglitazone, or sitagliptin).

192 utic options such as lifestyle modification, pioglitazone, or vitamin E.

193 The PPARgamma agonist pioglitazone partially rescued the adipogenic defect in

194 of lateral fluid percussion injury, combined pioglitazone (PG) and hMSC (combination) treatment showe

195 ing glitazone drugs, rosiglitazone (ROS) and pioglitazone (PGZ) both have anti-proliferative and anti

196 Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observ

197 tiveness of the selective PPAR-gamma agonist pioglitazone (PIO) for preventing hypoxia-induced IUGR.

198 Pioglitazone (Pio) is a Food and Drug Administration-app

199 ent showed improved molecular responses with pioglitazone, presumably through PPARgamma activation an

200 onstrate that the primary mechanism by which pioglitazone protects against polymicrobial sepsis is th

201 In this regard, pioglitazone provides advantages as a therapeutic tool,

202 Patients randomized to pioglitazone received the drug during a 16-week run-in p

203 Hippocampal microinjections of pioglitazone reduce the insurgence of the physical withd

204 Pioglitazone reduced risk for ischemic strokes (HR, 0.72

205 ondiabetics, the cumulative long-term use of pioglitazone reduced the dementia risk by 47% (RR = 0.53

206 Hippocampal microinjections of pioglitazone reduced the expression of the physical sign

207 Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of

208 nsulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndrom

209 Pioglitazone reduced the risk of acute coronary syndrome

210 Similarly, pioglitazone reduced the risk of large MIs with serum tr

211 reclinical and clinical data have shown that pioglitazone reduces alcohol and opioid self-administrat

212 ignaling activation by the selective agonist pioglitazone reduces alcohol drinking and alcohol-seekin

213 demonstrate that activation of PPARgamma by pioglitazone reduces the motivation for heroin and atten

214 Surprisingly, pioglitazone repressed TTF-1 expression in PPFP-expressi

215 In summary, pioglitazone reprogrammed BM macrophages and suppressed

216 Both metformin and pioglitazone resulted in a significant increase in the n

217 onectin protein concentration contributes to pioglitazone's ability to enhance HMW adiponectin levels

218 We also evaluated pioglitazone's effects on retinal function using electro

219 e treated with metformin and 10 who received pioglitazone showed a significant decrease in the number

220 beta cells, as islets from mice treated with pioglitazone showed reductions in PPAR-gamma (Ser-273) p

221 Patients treated with pioglitazone showed significant decreases in the mean (S

222 Pioglitazone showed similar efficacy as comparators in r

223 acrophages treated with a PPARgamma agonist (pioglitazone) showed enhanced phagocytosis and bacterial

224 Data demonstrate that 2 months of pioglitazone significantly increased electroretinogram a

225 demonstrated that (PPARgamma) activation by pioglitazone significantly inhibited both oxygen-glucose

226 Treatment with the PPARgamma agonist pioglitazone significantly reduced TFH cell responses in

227 Pioglitazone significantly rescues excessive intimal hyp

228 found that the synthetic PPARgamma agonist, pioglitazone, stimulated Abeta degradation by both micro

229 Additional studies with pioglitazone suggest that mitochondrial copper is target

230 menstrual cycle of females was inhibited by pioglitazone, suggesting that an estrogen-sufficient env

231 ed in both REC and Muller cells treated with pioglitazone, suggesting that these two cell types are k

232 In vitro, PPAR-gamma activation with pioglitazone switched macrophages from M1 to M2, reduced

233 nt ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo.

234 ent ischemic stroke or TIA to receive either pioglitazone (target dose, 45 mg daily) or placebo.

235 rction was lower among patients who received pioglitazone than among those who received placebo.

236 rthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NA

237 When mice were dosed with racemic pioglitazone, the concentration of (+)-pioglitazone was

238 Pioglitazone, the only thiazolidinedione drug in clinica

239 d, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-mediated insulin secretion a

240 In patients with diabetes on pioglitazone therapy, HSPC mobilization after G-CSF was

241 result in higher levels of brain exposure to pioglitazone, thus potentially improving the development

242 Furthermore, the effect of pioglitazone to control the inflammatory response during

243 nse to pioglitazone, and that the ability of pioglitazone to decrease TTF-1 expression contributes to

244 child with refractory NS by the addition of pioglitazone to the treatment correlated with marked red

245 rays of large myelinated sciatic nerves from pioglitazone-treated animals revealed an unanticipated i

246 Pioglitazone-treated mice showed identical weight gain,

247 cytokine production and high IL-10 levels in pioglitazone-treated mice.

248 Pioglitazone treatment also was associated with improvem

249 llular induction of Cxcl12 In diabetic mice, pioglitazone treatment downregulated Osm, p66Shc, and Cx

250 ence for age effects, nor for selection into pioglitazone treatment due to obesity.

251 p = 0.317), and diabetes patients without a pioglitazone treatment had a 23% increase in dementia ri

252 n a murine model of sepsis, we now show that pioglitazone treatment improves microbial clearance and

253 These findings indicate that pioglitazone treatment is associated with a reduced deme

254 Long-term pioglitazone treatment is safe and effective in patients

255 Moreover, although pioglitazone treatment normalized renal function, it had

256 hus potentially improving the development of pioglitazone treatment of AD.

257 Pioglitazone treatment of BKS db/db mice produced a sign

258 We sought to determine whether pioglitazone treatment of gp91(phox-/-) mice enhanced ph

259 It was hypothesized that pioglitazone treatment of gp91(phox-/-) mice, a murine m

260 The effect of 10 and 21 days of pioglitazone treatment on insulin sensitivity in 26 diab

261 Sildenafil or pioglitazone treatment prevented proteinuria and the inc

262 Pioglitazone treatment resulted in the phenotypic polari

263 concentrations of all oligomers increased on pioglitazone treatment, with the largest fold increase b

264 used GIP was unchanged following 12 weeks of pioglitazone treatment.

265 ollowed by an 18-month open-label phase with pioglitazone treatment.

266 nocytes from patients with CGD after ex vivo pioglitazone treatment.

267 n hyperplastic mechanism of weight gain with pioglitazone treatment.

268 titumor effect correlates with the fact that pioglitazone turns PPFP into a strongly PPARgamma-like m

269 We also investigate the stereoselectivity of pioglitazone uptake in the brain.

270 ntial increased risk for bladder cancer with pioglitazone use >/=3 years could not be excluded (OR: 1

271 risk (RR) of dementia incidence dependent on pioglitazone use adjusted for sex, age, use of rosiglita

272 Studies suggest pioglitazone use may increase risk of cancers.

273 Pioglitazone use was not associated with a statistically

274 sults were similar in case-control analyses (pioglitazone use: 19.6% among case patients and 17.5% am

275 Crude incidences of bladder cancer in pioglitazone users and nonusers were 89.8 and 75.9 per 1

276 idences of prostate and pancreatic cancer in pioglitazone users vs nonusers were 453.3 vs 449.3 and 8

277 ical Research Network Pathology Committee of Pioglitazone versus Vitamin E versus Placebo for the Tre

278 The PIVENS (Pioglitazone versus Vitamin E versus Placebo for the Tre

279 cemic pioglitazone, the concentration of (+)-pioglitazone was 46.6% higher than that of (-)-pioglitaz

280 Pioglitazone was also associated with a lower risk of di

281 Pure (+)-pioglitazone was also shown to have comparable amyloid-l

282 Pioglitazone was associated with a greater frequency of

283 Long-term use of pioglitazone was associated with a lower dementia incide

284 Pioglitazone was associated with a reduced risk for any

285 8 of the 10 additional cancers; ever use of pioglitazone was associated with increased risk of prost

286 Pioglitazone was effective for secondary prevention of i

287 When pioglitazone was given temporarily to three CML patients

288 The effect of pioglitazone was independent of actions on T cells, as p

289 Pioglitazone was less effective than troglitazone on all

290 In a direct comparison, pioglitazone was more cost-effective than vitamin E (ICE

291 Ever use of pioglitazone was not associated with bladder cancer risk

292 Sensitivity analyses indicated that pioglitazone was not cost-effective if either the total

293 LXR agonist GW3965 and the PPARgamma agonist pioglitazone were individually able to increase the leve

294 fic microinjections of the PPARgamma agonist pioglitazone were performed to explore the role of this

295 , and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily inj

296 significantly increases brain penetration of pioglitazone, whereas inhibition of breast cancer resist

297 The TZD pioglitazone, which has been approved by the U.S. Food a

298 rdial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might

299 New medications are being explored, such as pioglitazone, which is under study for its role in enhan

300 There was a significant association of pioglitazone with increased BW (WMD: 2.06 kg, 95% CI: 1.

301 Coadministration of pioglitazone with peginterferon/ribavirin improves insul